Non-Sponsored Content
Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety
By: News Feed | Last updated: 29th August 2018 | In: Cardiovascular
Article Keywords
AF, atrial fibrillation, Daiichi Sankyo, edoxaban, factor Xa, Lixiana, warfarin
Real-life use of edoxaban (Lixiana®, Daiichi Sankyo) in Asian atrial fibrillation (AF) patients significantly lowered the risk of ischaemic stroke (IS), intracranial haemorrhage (ICH), hospitalisation for gastrointestinal (GI) bleeding, hospitalisation for major bleeding, and all-cause death when compared to warfarin. This was concluded by the Korean investigators in the Journal of the American College of Cardiology. The benefits were consistent in the various high-risk subgroups.
The study registered new AF patients with prescriptions for either edoxaban (n=4,200) or warfarin (n=31,565) from the Korean National Health Insurance Service database. A propensity score matching method for edoxaban vs warfarin users balanced the covariates across the groups. The investigators analysed the risk of IS, ICH, hospitalisation for GI or major bleeding, and all-cause death.
The 1:3 propensity score−matched cohort of Korean AF patients encompassed 4,061 edoxaban and 12,183 warfarin users. Baseline characteristics were balanced between the two groups for age and CHA2DS2-VASc score (score 3).
Use of edoxaban was associated with a significantly decreased risk of IS (HR=0.693; 95% CI, 0.487-0.959), ICH (HR=0.407; 95% CI, 0.182-0.785), hospitalisation for GI bleeding (HR=0.597; 95% CI, 0.363-0.930), hospitalisation for major bleeding (HR=0.532; 95% CI, 0.352-0.773), and all-cause death (HR=0.716; 95% CI, 0.549-0.918) when compared to warfarin. Moreover, the improved clinical outcomes with edoxaban vs warfarin were consistent across all subgroups (age, sex, CHA2DS2-VASc score, renal function, edoxaban dose).
References
Lee SR, et al. J Am Coll Cardiol 2018: DOI: 10.1016/j.jacc.2018.05.066
Newsletter Sign-Up
Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.
Newsletter Sign-Up
YOU MAY ALSO LIKE
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd. – Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety.
YOU MAY ALSO LIKE
© Copyright 2018 MediPaper Medical Communications Ltd. – Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety.
Leave a Reply
Want to join the discussion?Feel free to contribute!